• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Cardiovascular disease - Articles and news items

Cardiovascular risk

Novartis invests in Ionis’ therapies to reduce cardiovascular risk

Industry news / 10 January 2017 / Niamh Marriott, Digital Editor

Novartis announced a collaboration and option agreement to license two novel treatments with the potential to significantly reduce cardiovascular risk…

FDA to review 3 new diabetes drugs that reduce cardiovascular death risk

Industry news / 5 January 2017 / Niamh Marriott, Digital Editor

In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%…

Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults

Industry news / 21 September 2016 / Niamh Louise Marriott, Digital Content Producer

Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent…

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

New data adds to understanding of Repatha® (evolocumab) in multiple patient populations

Industry news / 23 August 2016 / Amgen

Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome…

Controversy, media coverage and statin use in the UK

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

A study has found that controversy over the risks and benefits of statins was followed by an increase in people stopping their statin treatment…

Results in from Phase III CHART-1 study of C-Cure

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

Celyad has announced headline results for CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate – C-Cure…

NICE recommends alirocumab and evolocumab in draft guidance

Industry news / 6 May 2016 / Victoria White, Digital Content Producer

Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia…